Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

NEW YORK, April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. , an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice...

Related Keywords

,Synaptogenix Inc ,Drug Administration ,Nasdaq ,Listing Qualifications Department Of Nasdaq ,Nasdaq Stock Market ,Prnewswire Synaptogenix Inc ,Nasdaq Listing Rule ,Nasdaq Capital ,Listing Qualifications Department ,Listing Rule ,Orphan Drug Designation ,Markets ,